HSP763-01

HSP763-01 is a **novel fusion protein** that combines **glucagon-like peptide-1 (GLP-1)** and **fibroblast growth factor 21 (FGF21)** domains. It is designed as a dual agonist targeting both GLP-1 and FGF21 pathways, aiming for **synergistic pharmacological effects** in the treatment of metabolic diseases, specifically **non-alcoholic steatohepatitis (NASH)**. In preclinical studies, HSP763-01 demonstrated a significant reduction in body weight (without inducing appetite suppression), robust improvements in lipid metabolism (lowering triglycerides, total cholesterol, LDL), reduced blood glucose, and significant alleviation of hepatic steatosis and ballooning degeneration. It showed only partial efficacy on lobular inflammation and minimal effect in reversing advanced liver fibrosis in mouse models. The compound is intended for metabolic disorders such as obesity and NASH, and preclinical development was performed using mammalian expression systems[1][2][3][5][9].